News &amp; Updates

Dupilumab shows promise in bullous pemphigoid

Use of dupilumab appears to confer benefits in patients with bullous pemphigoid (BP), results of a recent study have shown. Treatment has resulted in disease clearance or satisfactory response in majority of the patients, including those in whom previous conventional therapy has failed.

Dupilumab shows promise in bullous pemphigoid

eGFR dip does not influence outcomes in T2D patients on empagliflozin

17 Jun 2020 by

An eGFR* decline of >10 percent did not appear to influence kidney outcomes in individuals receiving empagliflozin for type 2 diabetes, according to data presented at ERA-EDTA 2020.

eGFR dip does not influence outcomes in T2D patients on empagliflozin

Belimumab improves renal response in lupus nephritis

Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.

Belimumab improves renal response in lupus nephritis

Dabigatran use cuts risk of S. aureus bacteraemia in AF patients

Among patients with atrial fibrillation (AF), treatment with the direct thrombin inhibitor dabigatran results in a significantly lower incidence of Staphylococcus aureus bacteraemia as compared with factor Xa-inhibitors, a study has shown.

Dabigatran use cuts risk of S. aureus bacteraemia in AF patients

Regular aspirin use may reduce GI cancer risk

Regular use of aspirin may reduce the risk of gastrointestinal cancers, according to two studies presented at DDW 2020.

Regular aspirin use may reduce GI cancer risk

Apremilast proven effective in severe scalp psoriasis

Apremilast proven effective in severe scalp psoriasis

Extended therapy with rituximab reduces incidence of AAV relapse

Long-term therapy with biannual infusions of rituximab over 18 months, compared with standard maintenance therapy, results in a lower incidence of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse, a study has shown.

Extended therapy with rituximab reduces incidence of AAV relapse

Plecanatide favourable for older individuals with CIC, IBS-C

The guanylate cyclase-C receptor agonist plecanatide is effective and well-tolerated by older individuals (≥65 years) with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), results of a post hoc analysis presented at DDW 2020 has shown.

Plecanatide favourable for older individuals with CIC, IBS-C

$Benzodiazepine may pose increased fracture hazard in kids$

Benzodiazepine may pose increased fracture hazard in kids

Children with anxiety disorders receiving treatment with benzodiazepine are at high risk of fractures in the upper and lower limb than those taking selective serotonin reuptake inhibitors (SSRIs), an effect that is not observed in young adults, a study has found.

Benzodiazepine may pose increased fracture hazard in kids